Literature DB >> 28942623

Surveillance of hepatocellular carcinoma: is only ultrasound enough?

Woo Kyoung Jeong1.   

Abstract

Entities:  

Keywords:  Hepatocellular carcinoma; Magnetic resonance imaging (MRI); Surveillance; Ultrasonography

Mesh:

Year:  2017        PMID: 28942623      PMCID: PMC5628009          DOI: 10.3350/cmh.2017.0046

Source DB:  PubMed          Journal:  Clin Mol Hepatol        ISSN: 2287-2728


× No keyword cloud information.
See Article on 239 Early detection of hepatocellular carcinoma (HCC) is very important because the 5-year survival rate of early stage HCC (about 40% to 70%) is better than that of advanced stage HCC (less than 5%) [1]. In some countries, high-risk patients undergo a hepatocarcinoma surveillance program using ultrasound and serum alpha-fetoprotein (AFP) levels. However, there are several drawbacks of surveillance program using ultrasonography. For high chance of receiving curative treatment, the stage of HCC should be low, such as very early (BCLC 0) or early (BCLC A) stage. However, detection of small lesions by ultrasound is not easy. According to a meta-analysis [2], the sensitivity of ultrasonography was 65% to 80%. Although accompanying with measurement of serum AFP, the sensitivity to detect early HCC was not increased [3]. Therefore, it seems not to be enough to perform ultrasonography as the only imaging method for surveillance of HCC. According to a retrospective study by Wong, et al. [4] mean size of detected HCC lesion was 3.2 cm and 61% of patients (158/257) had a tumor less than 3 cm of the largest dimension. Another study performed by Kim, et al. [5] shows that only one tumor was detected by ultrasonography only among 1,100 screenings for 407 patients, but 26 cases were detected by the surveillance by magnetic resonance imaging (MRI). They said that MRI with hepatospecific agent such as gadoxetic acid (Gd-EOB-DTPA) is more sensitive than ultrasonography only to detect early stage HCC in high-risk patients. Additionally, MRI also showed a significantly lower false-positive rate and higher positive predictive value than ultrasonography. Moreover, their result of ultrasonographic surveillance (28%) was very poorer than that of meta-analysis (63%) [3], and they explained that a kind of lead-time bias and inherent distortions of the liver parenchyma by advanced cirrhosis affected the result. Although it was not appeared in these papers, variable level of ultrasonographic quality is one of the most important issues of ultrasonographic surveillance for HCC. In Korea, a nationwide screening program for HCC has been performed from 2003 as a part of the National Cancer Screening Program (NCSP), and its quality assessment was also performed. According to the report about the quality control of screening liver ultrasonography [6], 21% of hospitals (143/685) and 32% (645/1,985) of private clinics did not passed the quality assessment. In addition, there are some patients’ factors to interfere an ultrasonographic exam, such as obesity, coarse echotexture, thickened adipose tissue of abdominal wall, increased waist circumference, uncooperative patient, a lot of bowel gas, and difficulty of position change due to limited patients’ movement [4]. Apart from these limitations, ultrasonography still has an unconquerable limitation: ultrasonography is operator-dependent. The quality of exam by experienced operator is different from that by novice, and the result can be also different. To solve the problems of conventional imaging surveillance of HCC, we should consider introducing other objective imaging modalities such as CT or MRI. As mentioned above, the sensitivity of MRI to detect the curable HCC lesion which is able to be treated by locoregional treatments, such as resection, radiofrequency ablation, microwave ablation, and cryotherapy, was very significantly higher than that of ultrasonography. However, a major consideration is the cost-effectiveness of the surveillance program using MRI. Therefore, it would be desirable that MRI surveillance should be limited to those who will be able to be cured; for example, early stage HCC, compensated cirrhosis, and good performance status. Because the development risk of HCC is not same in the risk population, a tailored strategy using these imaging and serologic examinations should be considered. In addition, an effective quality assessment system for surveillance test including ultrasonography should be introduced and the surveillance program should be controlled to achieve the purpose of HCC surveillance.
  5 in total

1.  Surveillance for hepatocellular carcinoma: in whom and how?

Authors:  Hashem B El-Serag; Jessica A Davila
Journal:  Therap Adv Gastroenterol       Date:  2011-01       Impact factor: 4.409

2.  Quality Management of Ultrasound Surveillance for Hepatocellular Carcinoma Under the Korean National Cancer Screening Program.

Authors:  Moon Hyung Choi; Seung Eun Jung; Joon-Il Choi; Woo Kyoung Jeong; Hyun Cheol Kim; Yongsoo Kim; Yeol Kim; Boyoung Park
Journal:  J Ultrasound Med       Date:  2017-07-24       Impact factor: 2.153

3.  Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.

Authors:  A Singal; M L Volk; A Waljee; R Salgia; P Higgins; M A M Rogers; J A Marrero
Journal:  Aliment Pharmacol Ther       Date:  2009-04-08       Impact factor: 8.171

4.  Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world?

Authors:  Linda L Wong; Ruel J Reyes; Sandi A Kwee; Brenda Y Hernandez; Sumodh C Kalathil; Naoky C Tsai
Journal:  Clin Mol Hepatol       Date:  2017-07-14

5.  MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma.

Authors:  So Yeon Kim; Jihyun An; Young-Suk Lim; Seungbong Han; Ji-Young Lee; Jae Ho Byun; Hyung Jin Won; So Jung Lee; Han Chu Lee; Yung Sang Lee
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

  5 in total
  5 in total

Review 1.  Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Authors:  Sonal Krishan; Radha K Dhiman; Navin Kalra; Raju Sharma; Sanjay S Baijal; Anil Arora; Ajay Gulati; Anu Eapan; Ashish Verma; Shyam Keshava; Amar Mukund; S Deva; Ravi Chaudhary; Karthick Ganesan; Sunil Taneja; Ujjwal Gorsi; Shivanand Gamanagatti; Kumble S Madhusudan; Pankaj Puri; Shallini Govil; Manav Wadhavan; Sanjiv Saigal; Ashish Kumar; Shallini Thapar; Ajay Duseja; Neeraj Saraf; Anubhav Khandelwal; Sumit Mukhopadyay; Ajay Gulati; Nitin Shetty; Nipun Verma
Journal:  J Clin Exp Hepatol       Date:  2019-08-06

2.  Application of ultrasound combined with enhanced MRI by Gd-BOPTA in diagnosing hepatocellular carcinoma.

Authors:  Shuwen Ji; Ziyong Wang; Shiyong Xia
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response.

Authors:  Azeez Osho; Nicole E Rich; Amit G Singal
Journal:  Hepatoma Res       Date:  2020-08-27

4.  Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.

Authors:  Juliane Malik; Martin Klammer; Vinzent Rolny; Henry Lik-Yuen Chan; Teerha Piratvisuth; Tawesak Tanwandee; Satawat Thongsawat; Wattana Sukeepaisarnjaroen; Juan Ignacio Esteban; Marta Bes; Bruno Köhler; Magdalena Swiatek-de Lange
Journal:  World J Gastroenterol       Date:  2022-08-07       Impact factor: 5.374

5.  Exosomal microRNA-4661-5p-based serum panel as a potential diagnostic biomarker for early-stage hepatocellular carcinoma.

Authors:  Hyo Jung Cho; Geum Ok Baek; Chul Won Seo; Hye Ri Ahn; Suna Sung; Ju A Son; Soon Sun Kim; Sung Won Cho; Jeong Won Jang; Suk Woo Nam; Jae Youn Cheong; Jung Woo Eun
Journal:  Cancer Med       Date:  2020-06-14       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.